The Experts below are selected from a list of 327 Experts worldwide ranked by ideXlab platform
Jeffrey A. Lieberman - One of the best experts on this subject based on the ideXlab platform.
-
world federation of societies of biological psychiatry wfsbp guidelines for biological Treatment of Schizophrenia part 2 update 2012 on the long term Treatment of Schizophrenia and management of antipsychotic induced side effects
World Journal of Biological Psychiatry, 2013Co-Authors: Alkomiet Hasan, Peter Falkai, Thomas Wobrock, Jeffrey A. Lieberman, Wagner F. Gattaz, Florence Thibaut, B Glenthoj, Hansjurgen MollerAbstract:Abstract These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological Treatment of Schizophrenia published in 2006. For this 2012 revision, all available publications pertaining to the biological Treatment of Schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful. They are intended to be used by all physicians diagnosing and treating people suffering from Schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national Treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F) and five levels of recommendation (1-5) ( Bandelow et al. 2008a ,b, World J Biol Psychiatry 9:242, see Table 1 ). This second part of the updated guidelines covers long-term Treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological Treatment (including antipsychotic medication and other pharmacological Treatment options) of adults suffering from Schizophrenia.
-
world federation of societies of biological psychiatry wfsbp guidelines for biological Treatment of Schizophrenia part 1 update 2012 on the acute Treatment of Schizophrenia and the management of Treatment resistance
World Journal of Biological Psychiatry, 2012Co-Authors: Alkomiet Hasan, Birte Glenthøj, Peter Falkai, Thomas Wobrock, Jeffrey A. Lieberman, Wagner F. Gattaz, Florence Thibaut, Hansjurgen MollerAbstract:These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005. For this 2012 revision, all available publications pertaining to the biological Treatment of Schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful and these guidelines are intended to be used by all physicians diagnosing and treating people suffering from Schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national Treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F; Bandelow et al. 2008b, World J Biol Psychiatry 9:242). This first part of the updated guidelines covers the general descriptions of antipsychotics and their side effects, the biological Treatment of acute Schizophrenia and the management of Treatment-resistant Schizophrenia.
-
world federation of societies of biological psychiatry wfsbp guidelines for biological Treatment of Schizophrenia part 1 update 2012 on the acute Treatment of Schizophrenia and the management of Treatment resistance
World Journal of Biological Psychiatry, 2012Co-Authors: Alkomiet Hasan, Birte Glenthøj, Peter Falkai, Thomas Wobrock, Jeffrey A. Lieberman, Wagner F. Gattaz, Florence Thibaut, Hansjurgen MollerAbstract:These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005. For this 2012 revision, all available publications pertaining to the biological Treatment of Schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful and these guidelines are intended to be used by all physicians diagnosing and treating people suffering from Schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national Treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F; Bandelow et al. 2008b, World J Biol Psychiatry 9:242). This first part of the updated guidelines covers the general descriptions of antipsychotics and their side effects, the biological Treatment of acute Schizophrenia and the management of Treatment-resistant Schizophrenia.
-
Guidelines for biological Treatment of Schizophrenia, : Part 1: Acute Treatment of Schizophrenia and Part 2: Long-term Treatment of Schizophrenia
World Journal of Biological Psychiatry, 2008Co-Authors: Peter Falkai, Thomas Wobrock, Jeffrey A. Lieberman, Birte Yding Glenthøj, Wagner F. Gattaz, H-j Möller, A C Altamura, Niels Andreasen, Tre Barnes, Helmut BeckmannAbstract:Guidelines for biological Treatment of Schizophrenia, : Part 1: Acute Treatment of Schizophrenia and Part 2: Long-term Treatment of Schizophrenia
-
world federation of societies of biological psychiatry wfsbp guidelines for biological Treatment of Schizophrenia part 1 acute Treatment of Schizophrenia
World Journal of Biological Psychiatry, 2005Co-Authors: Peter Falkai, Birte Glenthøj, Thomas Wobrock, Jeffrey A. Lieberman, Wagner F. Gattaz, Hansjurgen Moller, Wfsbp Task Force On Treatment Guidelines For SchizophreniaAbstract:These guidelines for the biological Treatment of Schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the Treatment of Schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with Schizophrenia. The data used for developing these guidelines have been extracted primarily from various national Treatment guidelines and panels for Schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological Treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A � /D). This second part of the guidelines covers the long-term Treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological Treatment (including antipsychotic medication, other pharmacological Treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from Schizophrenia.
Birte Glenthøj - One of the best experts on this subject based on the ideXlab platform.
-
world federation of societies of biological psychiatry wfsbp guidelines for biological Treatment of Schizophrenia part 1 update 2012 on the acute Treatment of Schizophrenia and the management of Treatment resistance
World Journal of Biological Psychiatry, 2012Co-Authors: Alkomiet Hasan, Birte Glenthøj, Peter Falkai, Thomas Wobrock, Jeffrey A. Lieberman, Wagner F. Gattaz, Florence Thibaut, Hansjurgen MollerAbstract:These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005. For this 2012 revision, all available publications pertaining to the biological Treatment of Schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful and these guidelines are intended to be used by all physicians diagnosing and treating people suffering from Schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national Treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F; Bandelow et al. 2008b, World J Biol Psychiatry 9:242). This first part of the updated guidelines covers the general descriptions of antipsychotics and their side effects, the biological Treatment of acute Schizophrenia and the management of Treatment-resistant Schizophrenia.
-
world federation of societies of biological psychiatry wfsbp guidelines for biological Treatment of Schizophrenia part 1 update 2012 on the acute Treatment of Schizophrenia and the management of Treatment resistance
World Journal of Biological Psychiatry, 2012Co-Authors: Alkomiet Hasan, Birte Glenthøj, Peter Falkai, Thomas Wobrock, Jeffrey A. Lieberman, Wagner F. Gattaz, Florence Thibaut, Hansjurgen MollerAbstract:These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005. For this 2012 revision, all available publications pertaining to the biological Treatment of Schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful and these guidelines are intended to be used by all physicians diagnosing and treating people suffering from Schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national Treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F; Bandelow et al. 2008b, World J Biol Psychiatry 9:242). This first part of the updated guidelines covers the general descriptions of antipsychotics and their side effects, the biological Treatment of acute Schizophrenia and the management of Treatment-resistant Schizophrenia.
-
Serotonin 2A receptor antagonists for Treatment of Schizophrenia
Expert opinion on investigational drugs, 2011Co-Authors: Bjørn H. Ebdrup, Hans Rasmussen, Jørn Arnt, Birte GlenthøjAbstract:Introduction: All approved antipsychotic drugs share an affinity for the dopamine 2 (D2) receptor; however, these drugs only partially ameliorate the symptoms of Schizophrenia. It is, therefore, of paramount importance to identify new Treatment strategies for Schizophrenia. Areas covered: Preclinical, clinical and post-mortem studies of the serotonin 5-HT2A system in Schizophrenia are reviewed. The implications of a combined D2 and 5-HT2A receptor blockade, which is obtained by several current antipsychotic drugs, are discussed, and the rationale for the development of more selective 5-HT2A receptor antagonists is evaluated. Moreover, the investigational pipeline of major pharmaceutical companies is examined and an Internet search conducted to identify other pharmaceutical companies investigating 5-HT2A receptor antagonists for the Treatment of Schizophrenia. Expert opinion: 5-HT2A receptor antagonists appear to assume an intermediate position by being marginally superior to placebo but inferior to conven...
-
world federation of societies of biological psychiatry wfsbp guidelines for biological Treatment of Schizophrenia part 1 acute Treatment of Schizophrenia
World Journal of Biological Psychiatry, 2005Co-Authors: Peter Falkai, Birte Glenthøj, Thomas Wobrock, Jeffrey A. Lieberman, Wagner F. Gattaz, Hansjurgen Moller, Wfsbp Task Force On Treatment Guidelines For SchizophreniaAbstract:These guidelines for the biological Treatment of Schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the Treatment of Schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with Schizophrenia. The data used for developing these guidelines have been extracted primarily from various national Treatment guidelines and panels for Schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological Treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A � /D). This second part of the guidelines covers the long-term Treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological Treatment (including antipsychotic medication, other pharmacological Treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from Schizophrenia.
-
world federation of societies of biological psychiatry wfsbp guidelines for biological Treatment of Schizophrenia part 2 long term Treatment of Schizophrenia
World Journal of Biological Psychiatry, 2005Co-Authors: Peter Falkai, Birte Glenthøj, Thomas Wobrock, Jeffrey A. Lieberman, Wagner F. Gattaz, Hansjurgen Moller, Wfsbp Task Force On Treatment Guidelines For SchizophreniaAbstract:These guide lines for the biological Treatment of Schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBO). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the Treatment of Schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with Schizophrenia. The data used for developing these guidelines have been extracted primarily from various national Treatment guidelines and panels for Schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological Treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A-D). This first part of the guidelines covers disease definition, classification, epidemiology and course of Schizophrenia, as well as the management of the acute phase Treatment. These guidelines are primarily concerned with the biological Treatment (including antipsychotic medication, other pharmacological Treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from Schizophrenia.
John M. Kane - One of the best experts on this subject based on the ideXlab platform.
-
early response to antipsychotic drug therapy as a clinical marker of subsequent response in the Treatment of Schizophrenia
Neuropsychopharmacology, 2010Co-Authors: Bruce J Kinon, Lei Chen, Haya Aschersvanum, Virginia L Stauffer, Sara Kollackwalker, Wei Zhou, Shitij Kapur, John M. KaneAbstract:Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia
-
Psychopharmacologic Treatment of Schizophrenia
Schizophrenia bulletin, 1993Co-Authors: John M. Kane, Stephen R. MarderAbstract:The introduction of pharmacologic Treatments for Schizophrenia remains one of the major advances of twentieth century medicine. Despite the availability and efficacy of these compounds the Treatment of Schizophrenia continues to pose numerous challenges to clinicians, not only because of its prevalence, severity, and complexity, but also because its Treatment requires an integration of a variety of different prospectives (eg, biological, psychological, and psychosocial).1 Other chapters in this book have reviewed data relating to phenomenologic, genetic, neuroanatomic, psychophysiologic, and psychosocial aspects of this illness, providing extensive documentation of both its complexity and its probable heterogeneity.
-
New developments in the pharmacologic Treatment of Schizophrenia
Journal of Psychiatric Research, 1993Co-Authors: John M. KaneAbstract:Three of the most important developments in the Treatment of Schizophrenia over the past decade are the new generation of studies conducted on maintenance Treatment, the widespread introduction of clozapine and a renewed focus on negative symptoms
Peter Falkai - One of the best experts on this subject based on the ideXlab platform.
-
world federation of societies of biological psychiatry wfsbp guidelines for biological Treatment of Schizophrenia part 2 update 2012 on the long term Treatment of Schizophrenia and management of antipsychotic induced side effects
World Journal of Biological Psychiatry, 2013Co-Authors: Alkomiet Hasan, Peter Falkai, Thomas Wobrock, Jeffrey A. Lieberman, Wagner F. Gattaz, Florence Thibaut, B Glenthoj, Hansjurgen MollerAbstract:Abstract These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological Treatment of Schizophrenia published in 2006. For this 2012 revision, all available publications pertaining to the biological Treatment of Schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful. They are intended to be used by all physicians diagnosing and treating people suffering from Schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national Treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F) and five levels of recommendation (1-5) ( Bandelow et al. 2008a ,b, World J Biol Psychiatry 9:242, see Table 1 ). This second part of the updated guidelines covers long-term Treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological Treatment (including antipsychotic medication and other pharmacological Treatment options) of adults suffering from Schizophrenia.
-
world federation of societies of biological psychiatry wfsbp guidelines for biological Treatment of Schizophrenia part 1 update 2012 on the acute Treatment of Schizophrenia and the management of Treatment resistance
World Journal of Biological Psychiatry, 2012Co-Authors: Alkomiet Hasan, Birte Glenthøj, Peter Falkai, Thomas Wobrock, Jeffrey A. Lieberman, Wagner F. Gattaz, Florence Thibaut, Hansjurgen MollerAbstract:These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005. For this 2012 revision, all available publications pertaining to the biological Treatment of Schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful and these guidelines are intended to be used by all physicians diagnosing and treating people suffering from Schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national Treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F; Bandelow et al. 2008b, World J Biol Psychiatry 9:242). This first part of the updated guidelines covers the general descriptions of antipsychotics and their side effects, the biological Treatment of acute Schizophrenia and the management of Treatment-resistant Schizophrenia.
-
world federation of societies of biological psychiatry wfsbp guidelines for biological Treatment of Schizophrenia part 1 update 2012 on the acute Treatment of Schizophrenia and the management of Treatment resistance
World Journal of Biological Psychiatry, 2012Co-Authors: Alkomiet Hasan, Birte Glenthøj, Peter Falkai, Thomas Wobrock, Jeffrey A. Lieberman, Wagner F. Gattaz, Florence Thibaut, Hansjurgen MollerAbstract:These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005. For this 2012 revision, all available publications pertaining to the biological Treatment of Schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful and these guidelines are intended to be used by all physicians diagnosing and treating people suffering from Schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national Treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F; Bandelow et al. 2008b, World J Biol Psychiatry 9:242). This first part of the updated guidelines covers the general descriptions of antipsychotics and their side effects, the biological Treatment of acute Schizophrenia and the management of Treatment-resistant Schizophrenia.
-
Combination therapy in the Treatment of Schizophrenia.
Pharmacopsychiatry, 2010Co-Authors: Claus Wolff-menzler, Peter Falkai, Alkomiet Hasan, Berend Malchow, Thomas WobrockAbstract:Background: Although the international guidelines for the Treatment of Schizophrenia recommend antipsychotic monotherapy as the Treatment of choice, many Schizophrenia patients receive two or more antipsychotics in clinical practice, while co-Treatment with antidepressants, mood stabilizers and benzodiazepines is also common. Aim: The aim of the present review is to summarize the results of the randomized controlled trials of combination therapy versus monotherapy in Schizophrenia and to discuss possible implications of these results. Discussion: Altogether, recommendations are based upon theoretical assumptions rather than upon evidence-based knowledge regarding the combination of different antipsychotics or antipsychotics with other psychotropic agents in Schizophrenia Treatment, since the available studies reveal conflicting results. The augmentation with antidepressants for the Treatment of persisting negative symptoms and with mood stabilizers in patients with additional affective symptoms seems to be a successful strategy. Conclusions: Further randomized controlled trials are warranted to provide substantial evidence and to suggest combination strategies for Treatment-resistant Schizophrenia.
-
Guidelines for biological Treatment of Schizophrenia, : Part 1: Acute Treatment of Schizophrenia and Part 2: Long-term Treatment of Schizophrenia
World Journal of Biological Psychiatry, 2008Co-Authors: Peter Falkai, Thomas Wobrock, Jeffrey A. Lieberman, Birte Yding Glenthøj, Wagner F. Gattaz, H-j Möller, A C Altamura, Niels Andreasen, Tre Barnes, Helmut BeckmannAbstract:Guidelines for biological Treatment of Schizophrenia, : Part 1: Acute Treatment of Schizophrenia and Part 2: Long-term Treatment of Schizophrenia
Thomas Wobrock - One of the best experts on this subject based on the ideXlab platform.
-
world federation of societies of biological psychiatry wfsbp guidelines for biological Treatment of Schizophrenia part 2 update 2012 on the long term Treatment of Schizophrenia and management of antipsychotic induced side effects
World Journal of Biological Psychiatry, 2013Co-Authors: Alkomiet Hasan, Peter Falkai, Thomas Wobrock, Jeffrey A. Lieberman, Wagner F. Gattaz, Florence Thibaut, B Glenthoj, Hansjurgen MollerAbstract:Abstract These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological Treatment of Schizophrenia published in 2006. For this 2012 revision, all available publications pertaining to the biological Treatment of Schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful. They are intended to be used by all physicians diagnosing and treating people suffering from Schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national Treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F) and five levels of recommendation (1-5) ( Bandelow et al. 2008a ,b, World J Biol Psychiatry 9:242, see Table 1 ). This second part of the updated guidelines covers long-term Treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological Treatment (including antipsychotic medication and other pharmacological Treatment options) of adults suffering from Schizophrenia.
-
world federation of societies of biological psychiatry wfsbp guidelines for biological Treatment of Schizophrenia part 1 update 2012 on the acute Treatment of Schizophrenia and the management of Treatment resistance
World Journal of Biological Psychiatry, 2012Co-Authors: Alkomiet Hasan, Birte Glenthøj, Peter Falkai, Thomas Wobrock, Jeffrey A. Lieberman, Wagner F. Gattaz, Florence Thibaut, Hansjurgen MollerAbstract:These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005. For this 2012 revision, all available publications pertaining to the biological Treatment of Schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful and these guidelines are intended to be used by all physicians diagnosing and treating people suffering from Schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national Treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F; Bandelow et al. 2008b, World J Biol Psychiatry 9:242). This first part of the updated guidelines covers the general descriptions of antipsychotics and their side effects, the biological Treatment of acute Schizophrenia and the management of Treatment-resistant Schizophrenia.
-
world federation of societies of biological psychiatry wfsbp guidelines for biological Treatment of Schizophrenia part 1 update 2012 on the acute Treatment of Schizophrenia and the management of Treatment resistance
World Journal of Biological Psychiatry, 2012Co-Authors: Alkomiet Hasan, Birte Glenthøj, Peter Falkai, Thomas Wobrock, Jeffrey A. Lieberman, Wagner F. Gattaz, Florence Thibaut, Hansjurgen MollerAbstract:These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005. For this 2012 revision, all available publications pertaining to the biological Treatment of Schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful and these guidelines are intended to be used by all physicians diagnosing and treating people suffering from Schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national Treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F; Bandelow et al. 2008b, World J Biol Psychiatry 9:242). This first part of the updated guidelines covers the general descriptions of antipsychotics and their side effects, the biological Treatment of acute Schizophrenia and the management of Treatment-resistant Schizophrenia.
-
Combination therapy in the Treatment of Schizophrenia.
Pharmacopsychiatry, 2010Co-Authors: Claus Wolff-menzler, Peter Falkai, Alkomiet Hasan, Berend Malchow, Thomas WobrockAbstract:Background: Although the international guidelines for the Treatment of Schizophrenia recommend antipsychotic monotherapy as the Treatment of choice, many Schizophrenia patients receive two or more antipsychotics in clinical practice, while co-Treatment with antidepressants, mood stabilizers and benzodiazepines is also common. Aim: The aim of the present review is to summarize the results of the randomized controlled trials of combination therapy versus monotherapy in Schizophrenia and to discuss possible implications of these results. Discussion: Altogether, recommendations are based upon theoretical assumptions rather than upon evidence-based knowledge regarding the combination of different antipsychotics or antipsychotics with other psychotropic agents in Schizophrenia Treatment, since the available studies reveal conflicting results. The augmentation with antidepressants for the Treatment of persisting negative symptoms and with mood stabilizers in patients with additional affective symptoms seems to be a successful strategy. Conclusions: Further randomized controlled trials are warranted to provide substantial evidence and to suggest combination strategies for Treatment-resistant Schizophrenia.
-
Guidelines for biological Treatment of Schizophrenia, : Part 1: Acute Treatment of Schizophrenia and Part 2: Long-term Treatment of Schizophrenia
World Journal of Biological Psychiatry, 2008Co-Authors: Peter Falkai, Thomas Wobrock, Jeffrey A. Lieberman, Birte Yding Glenthøj, Wagner F. Gattaz, H-j Möller, A C Altamura, Niels Andreasen, Tre Barnes, Helmut BeckmannAbstract:Guidelines for biological Treatment of Schizophrenia, : Part 1: Acute Treatment of Schizophrenia and Part 2: Long-term Treatment of Schizophrenia
